- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT01594905
Entecavir Plus Tenofovir Combination in Subjects With Multi-drug Resistant Chronic Hepatitis B Virus Infection
A Multicenter, Open-label, Prospective Study to Evaluate Antiviral Efficacy and Safety of Entecavir Plus Tenofovir Combination in Subjects With Multi-drug Resistant Chronic Hepatitis B Virus Infection
Entecavir(ETV) plus Tenofovir Disoproxil Fumarate(TDF) combination will show effective antiviral activity and prevent further development of antiviral resistance in hepatitis B e antigen(HBeAg)-positive or -negative Chronic Hepatitis B(CHB) patients who experienced multidrug resistance
All subjects will orally take investigational drugs once daily for 48 weeks. All subjects will be assessed at baseline, Week 4, 12, 24, 36 and 48. Evaluations at each visit will include vital signs, physical examinations, laboratory tests and HBV DNA levels. They were also questioned about adverse events and concomitant medications. At baseline and every six months thereafter, serum will be assayed for HBV serology. Genotypic analysis will be performed at baseline and 48 weeks.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
- It has been one of unsolved issues and unmet needs in CHB management to develop an optimal combination regimen to manage multidrug resistant HBV characterized by selection of variants with two or more classes A of signature genotypic resistant mutations1-3
- Currently adding on Adefovir(ADV) has been generally recommended in Lamivudine(LAM)- or Telbivudine(LdT)-resistant patients but little is known about the optimal management of CHB patients who developed multidrug resistance4
- Recent report has shown that the combination of LAM plus ADV did not suppress HBV DNA effectively in CHB patients with resistance mutations to both drugs. Only 12.2% of these pts achieved virologic response(VR; HBV DNA <60 IU/mL) at 12 months and multivariable analysis showed that LAM+ADV group and the presence of the rtA181V/T mutation were independently associated with a decreased rate of virologic response (HBV DNA <2,000 IU/ml) at 12 months4
- ETV has been demonstrated to be effective in patients with ADV resistance but not in patients with proven YMDD mutation. In contrast, TDF has been shown to be effective in patients with YMDD mutation but not necessarily in all patients with ADV resistance.1-3
- Thus theoretically, the combination of the most potent nucleoside analogue and nucleotide analogue with non-overlapping resistance profiles, such as ETV plus TDF, is expected to be a promising salvage treatment for multidrug resistant HBV but clinical evidence is limited
- Therefore, this study will explore that adequate management of multidrug resistant patients using ETV plus TDF combination may lead to faster and greater viral suppression and prevent further emergence of antiviral resistance
All subjects will orally take investigational drugs once daily for 48 weeks. All subjects will be assessed at baseline, Week 4, 12, 24, 36 and 48. Evaluations at each visit will include vital signs, physical examinations, laboratory tests and HBV DNA levels. They were also questioned about adverse events and concomitant medications. At baseline and every six months thereafter, serum will be assayed for HBV serology. Genotypic analysis will be performed at baseline and 48 weeks.
Studientyp
Einschreibung (Voraussichtlich)
Phase
- Phase 4
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- ≥ 20 years of age
- History of HBsAg positive for more than 6 months
- Subject who has a history of genotypic resistance to NAs from two different classes A
- Detectable HBV DNA (≥ 60 IU/mL) while on any rescue treatment regimen for at least 24 weeks
- HBeAg-positive and -negative
- Compensated liver disease (Child-Pugh A)
- Signed written informed consent after being instructed about the objective and procedure of the clinical study
Exclusion Criteria:
- Subjects with Alanine Aminotransferase(ALT) > 10xUpper Limit of normal(ULN)
- Co-infected with hepatitis C virus(HCV) or HIV
- Pregnant or lactating woman
- Subject who needs long-term administration of drugs including immunosuppressive agents, agents related to high risk in the hepatic/renal toxicity, agents influencing renal excretion
- History of liver transplantation or planned for liver transplantation
- Subject who was diagnosed malignant tumor and has been receiving chemotherapy
- Subject who has hepatocellular carcinoma(HCC) history or who shows potential HCC finding such as suspicious region in the radiologic exam(abdominal US or CT) or serum Alpha Feto Protein(AFP) elevation
- Renal Insufficiency (CLcr < 50ml/min based on Cockcroft-Gault equation considering weight, ages and serum creatinine)
- Patient who has a liver disease other than chronic hepatitis B (e.g. hemochromatosis, Wilson's disease, alcoholic liver disease, nonalcoholic fatty liver disease, alpha 1-antitrypsin deficiency etc.)
- Subject who has a history of hypersensitivity to study drug or its ingredients
- Subject who is involved in other clinical trial within 60 days prior to study entry
- Subject who the investigator deems inappropriate to participate in this study
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: N / A
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Experimental: Entecavir 1.0mg + Tenofovir 300mg
All subjects will orally take investigational drugs once daily for 48 weeks.
|
Entecavir 1.0mg + Tenofovir 300mg
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
The proportion of subjects who achieve virologic response(HBV DNA < 60 IU/mL, approximately 300 copies/mL) by real-time PCR at Week 48
Zeitfenster: at Week 48
|
To evaluate the proportion of subjects who achieve virologic response(HBV DNA < 60 IU/mL, approximately 300 copies/mL) by real-time Polymerase chain reaction(PCR) at Week 48 after Entecavir plus Tenofovir combination therapy
|
at Week 48
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Virologic, serologic, biochemical efficacy and safety profile, as measured by the incidence of clinical adverse events and laboratory abnormalities including renal marker
Zeitfenster: Week 4, 12, 24, 36, and 48
|
To evaluate virologic, serologic and biochemical response and safety of Entecavir plus Tenofovir combination therapy for 48 weeks
|
Week 4, 12, 24, 36, and 48
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Hauptermittler: Sang Hoon Ahn, MD, PhD, Yonsei University
Publikationen und hilfreiche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Voraussichtlich)
Studienabschluss (Voraussichtlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Erkrankungen des Verdauungssystems
- RNA-Virusinfektionen
- Infektionen
- Durch Blut übertragene Infektionen
- Übertragbare Krankheiten
- Leberkrankheiten
- Hepatitis, viral, menschlich
- Hepadnaviridae-Infektionen
- DNA-Virusinfektionen
- Enterovirus-Infektionen
- Picornaviridae-Infektionen
- Hepatitis B
- Hepatitis
- Hepatitis A
- Viruserkrankungen
- Hepatitis B, chronisch
- Hepatitis, chronisch
- Herpesviridae-Infektionen
- Molekulare Mechanismen der pharmakologischen Wirkung
- Antiinfektiva
- Antivirale Mittel
- Reverse-Transkriptase-Inhibitoren
- Inhibitoren der Nukleinsäuresynthese
- Enzym-Inhibitoren
- Anti-HIV-Agenten
- Antiretrovirale Mittel
- Tenofovir
- Entecavir
Andere Studien-ID-Nummern
- AI463-273
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Chronische Hepatitis B
-
The Affiliated Nanjing Drum Tower Hospital of Nanjing...Gilead SciencesNoch keine Rekrutierung
-
Third Affiliated Hospital, Sun Yat-Sen UniversityRekrutierungChronische Hepatitis b | Zirrhose durch Hepatitis BChina
-
Nanfang Hospital of Southern Medical UniversityRekrutierung
-
IlDong Pharmaceutical Co LtdRekrutierungChronische Hepatitis bKorea, Republik von
-
Antios Therapeutics, IncBeendetChronische Hepatitis bVereinigte Staaten
-
Xi'an Xintong Pharmaceutical Research Co.,Ltd.Unbekannt
-
National Taiwan University HospitalChiayi Christian Hospital; E-DA Hospital; Taipei City Hospital; Taipei Tzu Chi Hospital... und andere MitarbeiterRekrutierungPatienten mit chronischer Hepatitis b stellen nach Absetzen des Nukleosidanalogs auf tAf um (CHANGE)Chronische Hepatitis b | Hepatitis-B-ReaktivierungTaiwan
-
Mahidol UniversityUnbekanntChronische Hepatitis B, HBsAg, Hepatitis-B-ImpfstoffThailand
-
Tongji HospitalChia Tai Tianqing Pharmaceutical Group Co., Ltd.UnbekanntChronische Hepatitis b
-
Tongji HospitalGilead SciencesRekrutierung
Klinische Studien zur Entecavir + Tenofovir (MDR group)
-
Cytheris SAUnbekanntChronische Hepatitis BFrankreich, Italien
-
Third Affiliated Hospital, Sun Yat-Sen UniversityUnbekannt
-
E-DA HospitalAktiv, nicht rekrutierendChronische Hepatitis bTaiwan
-
Zhongshan Hospital (Xiamen), Fudan UniversityRekrutierungHepatozelluläres Karzinom | Chronische Hepatitis BChina
-
Enyo PharmaParexel; Novotech (Australia) Pty Limited; Synteract, Inc.; EurofinsBeendetHepatitis B, chronischAustralien, Hongkong, Korea, Republik von, Polen
-
Korea UniversityGilead SciencesAbgeschlossenChronische Hepatitis BKorea, Republik von
-
University of California, San FranciscoBristol-Myers SquibbAbgeschlossenHIV-Infektionen | Hepatitis BVereinigte Staaten
-
Bristol-Myers SquibbBeendetChronische Hepatitis BDeutschland, Truthahn, Vereinigte Staaten, Polen, Belgien, Italien
-
TetraLogic PharmaceuticalsBeendetHepatitis BAustralien
-
Shanghai Nanhui Nanhua HospitalAktiv, nicht rekrutierend